Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL-Reference-Cited by-同舟云学术

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL

Published:2014-06-12 Issue:24 Volume:123 Page:3727-3732
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Strati Paolo¹,Keating Michael J.¹,O'Brien Susan M.¹,Burger Jan¹,Ferrajoli Alessandra¹,Jain Nitin¹,Tambaro Francesco Paolo²,Estrov Zeev¹,Jorgensen Jeffrey³,Challagundla Pramoda³,Faderl Stefan H.¹,Wierda William G.¹

Affiliation:

1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;

2. Dipartimento di Patologia Generale, Seconda Università degli Studi di Napoli, Napoli, Italy; and

3. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Abstract

Key Points MRD eradication is a desirable end point in chronic lymphocytic leukemia. Early MRD eradication may prompt treatment discontinuation.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/24/3727/1377477/3727.pdf

Reference23 articles.

1. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.;Keating;J Clin Oncol,2005

2. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.;Hallek;Lancet,2010

3. Assessment of minimal residual disease in acute myeloid leukemia.;Grimwade;Curr Opin Oncol,2010

4. Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?;Campana;Curr Hematol Malig Rep,2012

5. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.;Jabbour;Am J Hematol,2012

Cited by 134 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia;JAMA Oncology;2024-07-11

2. What clinicians should know about surrogate end points in hematologic malignancies;Blood;2024-07-04

3. Performance of a novel eight‐color flow cytometry panel for measurable residual disease assessment of chronic lymphocytic leukemia;Cytometry Part B: Clinical Cytometry;2024-03-27

4. Impact of Binet Staging versus Tumour Bulk on Treatment Outcome in Chronic Lymphocytic Leukaemia;Nigerian Postgraduate Medical Journal;2024-01

5. Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study;Journal of Clinical Oncology;2023-12-14